Compare Boston Beer Company Inc (SAM) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs DENTSPLY SIRONA Inc — how do they compare? Boston Beer Company Inc trades at $163.71 (market cap $1.67B), while DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B). The key difference: DENTSPLY SIRONA Inc is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | XRAY | |
|---|---|---|
Market Cap | $1.67B | $2.19B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $14.68 |
52-Week Low | $161.08 | $9.64 |
Enterprise Value | $1.43B | $4.26B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Boston Beer Company (SAM) trades at $162.06, down 3.98% today, showing mixed signals with bearish technical indicators but positive cash flow trends. Recent earnings have missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains a debt-free balance sheet with strong operating cash flow of $270M in 2025, but faces volume declines and margin pressure.
SAM presents a cautious outlook with analyst consensus leaning Hold (71.87%) despite a $207.33 price target suggesting 28% upside. Key risks include declining alcohol consumption and execution challenges, while opportunities lie in new product launches and marketing leadership changes. The stock's valuation appears reasonable with P/E of 22.66 and P/S of 0.89.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.
The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
